Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Skin sensitization testing needs and data uses by US regulatory and research agencies.

Strickland J, Daniel AB, Allen D, Aguila C, Ahir S, Bancos S, Craig E, Germolec D, Ghosh C, Hudson NL, Jacobs A, Lehmann DM, Matheson J, Reinke EN, Sadrieh N, Vukmanovic S, Kleinstreuer N.

Arch Toxicol. 2019 Feb;93(2):273-291. doi: 10.1007/s00204-018-2341-6. Epub 2018 Oct 30.

PMID:
30377734
2.

FDA 2014 survey of eye area cosmetics for microbiological safety.

Periz G, Misock J, Huang MJ, Dewan K, Sadrieh N.

Lett Appl Microbiol. 2018 Jul;67(1):32-38. doi: 10.1111/lam.12995. Epub 2018 May 7.

PMID:
29665083
3.

Dihydroxyacetone: A Review.

Braunberger TL, Nahhas AF, Katz LM, Sadrieh N, Lim HW.

J Drugs Dermatol. 2018 Apr 1;17(4):387-391. Review.

PMID:
29601614
4.

In chemico skin sensitization risk assessment of botanical ingredients.

Avonto C, Chittiboyina AG, Sadrieh N, Vukmanovic S, Khan IA.

J Appl Toxicol. 2018 Jul;38(7):1047-1053. doi: 10.1002/jat.3614. Epub 2018 Mar 24.

PMID:
29572967
5.

Microbiological survey of commercial tattoo and permanent makeup inks available in the United States.

Nho SW, Kim SJ, Kweon O, Howard PC, Moon MS, Sadrieh NK, Cerniglia CE.

J Appl Microbiol. 2018 May;124(5):1294-1302. doi: 10.1111/jam.13713. Epub 2018 Mar 12.

PMID:
29388315
6.

Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening.

Vukmanović S, Sadrieh N.

Crit Rev Toxicol. 2017 May;47(5):415-432. doi: 10.1080/10408444.2017.1288025. Epub 2017 Mar 22. Review. Erratum in: Crit Rev Toxicol. 2017 May;47(5):i.

PMID:
28326907
7.

Reporting Cosmetic Adverse Events to the US Food and Drug Administration.

Katz LM, Valenzuela C, Sadrieh NK.

Dermatitis. 2016 Jul-Aug;27(4):236-7. doi: 10.1097/DER.0000000000000195. No abstract available.

PMID:
27323232
8.

Optimization and dissolution performance of spray-dried naproxen nano-crystals.

Kumar S, Shen J, Zolnik B, Sadrieh N, Burgess DJ.

Int J Pharm. 2015;486(1-2):159-66. doi: 10.1016/j.ijpharm.2015.03.047. Epub 2015 Mar 23.

PMID:
25814034
9.

Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Bartlett JA, Brewster M, Brown P, Cabral-Lilly D, Cruz CN, David R, Eickhoff WM, Haubenreisser S, Jacobs A, Malinoski F, Morefield E, Nalubola R, Prud'homme RK, Sadrieh N, Sayes CM, Shahbazian H, Subbarao N, Tamarkin L, Tyner K, Uppoor R, Whittaker-Caulk M, Zamboni W.

AAPS J. 2015 Jan;17(1):44-64. doi: 10.1208/s12248-014-9701-9. Epub 2014 Nov 25.

10.

Formulation and performance of danazol nano-crystalline suspensions and spray dried powders.

Kumar S, Jog R, Shen J, Zolnik B, Sadrieh N, Burgess DJ.

Pharm Res. 2015 May;32(5):1694-703. doi: 10.1007/s11095-014-1567-0. Epub 2014 Nov 11.

PMID:
25385690
11.

In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole.

Kumar S, Jog R, Shen J, Zolnik B, Sadrieh N, Burgess DJ.

J Pharm Sci. 2015 Sep;104(9):3018-28. doi: 10.1002/jps.24155. Epub 2014 Sep 5.

PMID:
25195539
12.

Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization".

Finch G, Havel H, Analoui M, Barton RW, Diwan AR, Hennessy M, Reddy V, Sadrieh N, Tamarkin L, Wolfgang M, Yerxa B, Zolnik B, Liu M.

AAPS J. 2014 Jul;16(4):698-704. doi: 10.1208/s12248-014-9608-5. Epub 2014 May 13.

13.

Ethinyl estradiol and other human pharmaceutical estrogens in the aquatic environment: a review of recent risk assessment data.

Laurenson JP, Bloom RA, Page S, Sadrieh N.

AAPS J. 2014 Mar;16(2):299-310. doi: 10.1208/s12248-014-9561-3. Epub 2014 Jan 28. Review.

14.

A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities.

Valencia A, Prous J, Mora O, Sadrieh N, Valerio LG Jr.

Toxicol Appl Pharmacol. 2013 Dec 15;273(3):427-34. doi: 10.1016/j.taap.2013.09.015. Epub 2013 Sep 30.

PMID:
24090816
15.

Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs.

Chen ML, Sadrieh N, Yu L.

AAPS J. 2013 Oct;15(4):1043-50. doi: 10.1208/s12248-013-9509-z. Epub 2013 Jul 19. Review. No abstract available.

16.

In silico modeling to predict drug-induced phospholipidosis.

Choi SS, Kim JS, Valerio LG Jr, Sadrieh N.

Toxicol Appl Pharmacol. 2013 Jun 1;269(2):195-204. doi: 10.1016/j.taap.2013.03.010. Epub 2013 Mar 27.

PMID:
23541745
17.

Development of cardiac safety translational tools for QT prolongation and torsade de pointes.

Valerio LG Jr, Balakrishnan S, Fiszman ML, Kozeli D, Li M, Moghaddam S, Sadrieh N.

Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):801-15. doi: 10.1517/17425255.2013.783819. Epub 2013 Mar 28.

PMID:
23537164
18.

CDER risk assessment exercise to evaluate potential risks from the use of nanomaterials in drug products.

Cruz CN, Tyner KM, Velazquez L, Hyams KC, Jacobs A, Shaw AB, Jiang W, Lionberger R, Hinderling P, Kong Y, Brown PC, Ghosh T, Strasinger C, Suarez-Sharp S, Henry D, Van Uitert M, Sadrieh N, Morefield E.

AAPS J. 2013 Jul;15(3):623-8. doi: 10.1208/s12248-013-9466-6. Epub 2013 Mar 20.

19.

Tissue distribution and histopathological effects of titanium dioxide nanoparticles after intravenous or subcutaneous injection in mice.

Umbreit TH, Francke-Carroll S, Weaver JL, Miller TJ, Goering PL, Sadrieh N, Stratmeyer ME.

J Appl Toxicol. 2012 May;32(5):350-7. doi: 10.1002/jat.1700. Epub 2011 Aug 25.

PMID:
22447616
20.

The state of nano-sized titanium dioxide (TiO2) may affect sunscreen performance.

Tyner KM, Wokovich AM, Godar DE, Doub WH, Sadrieh N.

Int J Cosmet Sci. 2011 Jun;33(3):234-44. doi: 10.1111/j.1468-2494.2010.00622.x. Epub 2011 Jan 25.

PMID:
21265867
21.

Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats.

Rouse RL, Zhang J, Stewart SR, Rosenzweig BA, Espandiari P, Sadrieh NK.

Kidney Int. 2011 Jun;79(11):1186-97. doi: 10.1038/ki.2010.463. Epub 2010 Dec 8.

22.

Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.

Tyner K, Sadrieh N.

Methods Mol Biol. 2011;697:17-31. doi: 10.1007/978-1-60327-198-1_3.

PMID:
21116951
23.

Gold nanoparticle trafficking of typically excluded compounds across the cell membrane in JB6 Cl 41-5a cells causes assay interference.

Keene AM, Allaway RJ, Sadrieh N, Tyner KM.

Nanotoxicology. 2011 Dec;5(4):469-78. doi: 10.3109/17435390.2010.533792. Epub 2010 Nov 19.

PMID:
21090919
24.

Nanotechnology and therapeutic delivery: a drug regulation perspective.

Sadrieh N, Tyner KM.

Ther Deliv. 2010 Jul;1(1):83-9.

PMID:
22816122
25.

Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles.

Sadrieh N, Wokovich AM, Gopee NV, Zheng J, Haines D, Parmiter D, Siitonen PH, Cozart CR, Patri AK, McNeil SE, Howard PC, Doub WH, Buhse LF.

Toxicol Sci. 2010 May;115(1):156-66. doi: 10.1093/toxsci/kfq041. Epub 2010 Feb 15.

26.

Nanoparticles and the immune system.

Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA.

Endocrinology. 2010 Feb;151(2):458-65. doi: 10.1210/en.2009-1082. Epub 2009 Dec 16. Review.

27.

Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin.

Prodduturi S, Sadrieh N, Wokovich AM, Doub WH, Westenberger BJ, Buhse L.

J Pharm Sci. 2010 May;99(5):2357-66. doi: 10.1002/jps.22004.

PMID:
19967778
28.

Age-related differences in susceptibility to cisplatin-induced renal toxicity.

Espandiari P, Rosenzweig B, Zhang J, Zhou Y, Schnackenberg L, Vaidya VS, Goering PL, Brown RP, Bonventre JV, Mahjoob K, Holland RD, Beger RD, Thompson K, Hanig J, Sadrieh N.

J Appl Toxicol. 2010 Mar;30(2):172-82. doi: 10.1002/jat.1484.

29.

Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using CE coupled with MS as a potential model for detection of drug-induced adverse effects.

Mischak H, Espandiari P, Sadrieh N, Hanig J.

Proteomics Clin Appl. 2009 Sep;3(9):1062-71. doi: 10.1002/prca.200900030. Epub 2009 Aug 26.

PMID:
21137006
30.

Energy dispersive X-ray analysis of titanium dioxide nanoparticle distribution after intravenous and subcutaneous injection in mice.

Patri A, Umbreit T, Zheng J, Nagashima K, Goering P, Francke-Carroll S, Gordon E, Weaver J, Miller T, Sadrieh N, McNeil S, Stratmeyer M.

J Appl Toxicol. 2009 Nov;29(8):662-72. doi: 10.1002/jat.1454.

PMID:
19626582
31.

Particle size determination of sunscreens formulated with various forms of titanium dioxide.

Wokovich A, Tyner K, Doub W, Sadrieh N, Buhse LF.

Drug Dev Ind Pharm. 2009 Oct;35(10):1180-9. doi: 10.1080/03639040902838043.

PMID:
19555241
32.

Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine.

Zhang J, Goering PL, Espandiari P, Shaw M, Bonventre JV, Vaidya VS, Brown RP, Keenan J, Kilty CG, Sadrieh N, Hanig JP.

Toxicol Pathol. 2009 Aug;37(5):629-43. doi: 10.1177/0192623309339605. Epub 2009 Jun 17.

33.

Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.

Zolnik BS, Sadrieh N.

Adv Drug Deliv Rev. 2009 Jun 21;61(6):422-7. doi: 10.1016/j.addr.2009.03.006. Epub 2009 Apr 20. Review.

PMID:
19389437
34.

Comparing methods for detecting and characterizing metal oxide nanoparticles in unmodified commercial sunscreens.

Tyner KM, Wokovich AM, Doub WH, Buhse LF, Sung LP, Watson SS, Sadrieh N.

Nanomedicine (Lond). 2009 Feb;4(2):145-59. doi: 10.2217/17435889.4.2.145.

PMID:
19193182
35.

Evaluation of substrates for 90 degrees peel adhesion--a collaborative study. II. Transdermal drug delivery systems.

Wokovich AM, Brown SA, Shen M, Doub WH, Cai B, Sadrieh N, Chen ML, Machado S, Buhse LF.

J Biomed Mater Res B Appl Biomater. 2009 Jan;88(1):61-5. doi: 10.1002/jbm.b.31149.

PMID:
18546200
36.

Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: relationship to renal distributions of iNOS and nitrotyrosine.

Zhang J, Brown RP, Shaw M, Vaidya VS, Zhou Y, Espandiari P, Sadrieh N, Stratmeyer M, Keenan J, Kilty CG, Bonventre JV, Goering PL.

Toxicol Pathol. 2008 Apr;36(3):397-409. doi: 10.1177/0192623308315832. Epub 2008 Apr 25.

37.

Evaluation of substrates for 90 degrees peel adhesion--a collaborative study. I. Medical tapes.

Wokovich AM, Brown SA, McMaster FJ, Doub WH, Cai B, Sadrieh N, Chen ML, Machado S, Shen M, Buhse LF.

J Biomed Mater Res B Appl Biomater. 2008 Oct;87(1):105-13. doi: 10.1002/jbm.b.31075.

PMID:
18386842
38.

Quantitative determination of cesium binding to ferric hexacyanoferrate: Prussian blue.

Faustino PJ, Yang Y, Progar JJ, Brownell CR, Sadrieh N, May JC, Leutzinger E, Place DA, Duffy EP, Houn F, Loewke SA, Mecozzi VJ, Ellison CD, Khan MA, Hussain AS, Lyon RC.

J Pharm Biomed Anal. 2008 May 12;47(1):114-25. doi: 10.1016/j.jpba.2007.11.049. Epub 2007 Dec 14.

PMID:
18242038
39.

Quantitative determination of thallium binding to ferric hexacyanoferrate: Prussian blue.

Yang Y, Faustino PJ, Progar JJ, Brownell CR, Sadrieh N, May JC, Leutzinger E, Place DA, Duffy EP, Yu LX, Khan MA, Lyon RC.

Int J Pharm. 2008 Apr 2;353(1-2):187-94. doi: 10.1016/j.ijpharm.2007.11.031. Epub 2007 Nov 23.

PMID:
18226478
40.

Quantitative measurement of cyanide released from Prussian Blue.

Yang Y, Brownell C, Sadrieh N, May J, Del A.

Clin Toxicol (Phila). 2007 Oct-Nov;45(7):776-81.

PMID:
17924254
41.

Validation of an in vitro method for the determination of cyanide release from ferric-hexacyanoferrate: Prussian blue.

Yang Y, Brownell CR, Sadrieh N, May JC, Del Grosso AV, Lyon RC, Faustino PJ.

J Pharm Biomed Anal. 2007 Mar 12;43(4):1358-63. Epub 2006 Dec 14.

PMID:
17174056
42.

A modern view of excipient effects on bioequivalence: case study of sorbitol.

Chen ML, Straughn AB, Sadrieh N, Meyer M, Faustino PJ, Ciavarella AB, Meibohm B, Yates CR, Hussain AS.

Pharm Res. 2007 Jan;24(1):73-80. Epub 2006 Oct 18.

PMID:
17048115
43.

Research strategies for safety evaluation of nanomaterials, part VII: evaluating consumer exposure to nanoscale materials.

Thomas T, Thomas K, Sadrieh N, Savage N, Adair P, Bronaugh R.

Toxicol Sci. 2006 May;91(1):14-9. Epub 2006 Feb 13.

PMID:
16476686
44.

Stability, dose uniformity, and palatability of three counterterrorism drugs-human subject and electronic tongue studies.

Sadrieh N, Brower J, Yu L, Doub W, Straughn A, Machado S, Pelsor F, Martin ES, Moore T, Reepmeyer J, Toler D, Nguyenpho A, Roberts R, Schuirmann DJ, Nasr M, Buhse L.

Pharm Res. 2005 Oct;22(10):1747-56. Epub 2005 Sep 22.

PMID:
16180133
45.
46.

Metabolism of food-derived heterocyclic amines in nonhuman primates.

Snyderwine EG, Turesky RJ, Turteltaub KW, Davis CD, Sadrieh N, Schut HA, Nagao M, Sugimura T, Thorgeirsson UP, Adamson RH, Thorgeirsson SS.

Mutat Res. 1997 May 12;376(1-2):203-10.

PMID:
9202757
47.

Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin.

Ghosal A, Sadrieh N, Reik L, Levin W, Thomas PE.

Arch Biochem Biophys. 1996 Aug 1;332(1):153-62.

PMID:
8806720
48.
50.

In vivo effects of chromium.

Witmer C, Faria E, Park HS, Sadrieh N, Yurkow E, O'Connell S, Sirak A, Schleyer H.

Environ Health Perspect. 1994 Sep;102 Suppl 3:169-76.

Supplemental Content

Loading ...
Support Center